Olfr63, a pivotal member of the olfactory receptor family, plays a central role in the intricate process of olfaction. As a G-protein-coupled receptor (GPCR) located in the nasal epithelium, Olfr63 is crucial for detecting and transducing signals from various odorant molecules. The structural foundation of Olfr63, characterized by its 7-transmembrane domain architecture, enables its interaction with a diverse range of odorants, contributing to the richness and complexity of our sense of smell. Within the expansive olfactory receptor gene family, Olfr63 stands out as a key mediator of the initial steps in olfactory signal processing, initiating the cascade that leads to the perception of distinct odors.
The inhibition of Olfr63 involves a sophisticated interplay of various chemical compounds and cellular processes. Direct inhibitors target Olfr63 or associated pathways, disrupting the olfactory signal transduction cascade at different stages. These inhibitors may interfere with phosphorylation events, alter downstream components, or modulate specific signaling pathways such as MAPK, PI3K-Akt, JNK, TGF-β, and NF-κB. Indirect inhibitors, on the other hand, impact cellular processes associated with Olfr63 function without directly targeting the receptor. By influencing signaling pathways, these compounds create a nuanced network of interactions that collectively contribute to the inhibition of Olfr63. The comprehensive understanding of these mechanisms not only sheds light on the molecular intricacies of olfaction but also provides insights into potential strategies for modulating olfactory receptors in diverse contexts, contributing to our broader understanding of sensory perception and receptor regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits the PI3K/Akt pathway, which may indirectly affect Olfr63 through downstream signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, potentially impacting Olfr63 by modulating the PI3K/Akt pathway and downstream signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could indirectly influence Olfr63 by modulating the p38 MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that may indirectly suppress Olfr63 by inhibiting the MAPK pathway and downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, potentially affecting Olfr63 expression through its regulation of the mTOR pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that might indirectly influence Olfr63 through the JNK pathway and its downstream effects. | ||||||